Nikol Mraz

Ms. Nikol Mraz

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in BBA Advances
Verified
Journal Article
Open access
LSLucija Sironić
Lucija Sironić
NMNikol Mraz
Nikol Mraz
GLGordan Lauc
Gordan Lauc
TKThomas Klarić
Thomas Klarić
• What is known about phosphorylation of N-glycans in the brain is reviewed in detail. • Phosphorylated N-glycans of the brain exhibit several distinctive features. • N-glycans of lysosomal and non-lysosomal proteins are phosphorylated differently. • Does the brain employ a non-canonical oligosaccharide phosphorylation mechanism?. • Evidence underpinning this hypothesis is presented and discussed.

22 June 2026 in medRxiv
Verified
Preprint
Open access
NMNikol Mraz
Nikol Mraz
FVFrano Vučković
Frano Vučković
TPTea Pribić
Tea Pribić
AKAnica Radoš Kajić
Anica Radoš Kajić
TMTomas Matić
Tomas Matić
TŠTamara Štambuk
Tamara Štambuk
Introduction: Diabetes is a growing global health challenge, necessitating effective management strategies. Glycosylation, a highly regulated post-translational protein modification, has emerged as a pivotal factor in diabetes pathophysiology. However, the modulation of protein glycosylation by antidiabetic treatment is still largely unknown. This study explored the longitudinal effects of four distinct antidiabetic therapies – metformin, insulin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 receptor agonists (GLP-1RA) – on plasma protein and immunoglobulin G (IgG) glycosylation in patients with type 2 diabetes (T2D). Research Design and Methods: Plasma protein and IgG N-glycans were enzymatically released, purified and chromatographically profiled in a cohort of 124 patients, examined at four time points, to assess therapy-induced glycan alterations. Linear mixed models adjusting for covariates and multiple testing (FDR<0.05) were used to investigate the associations between plasma protein and IgG N-glycosylation and antidiabetic therapy. Results: Our findings reveal that metformin, SGLT2 inhibitors, and GLP-1RA induce significant alterations in IgG glycosylation, including the increased core fucosylation and galactosylation, features associated with a reduced inflammatory IgG potential. Notably, IgG monogalactosylation, previously linked to cardioprotective effects in women, was elevated in response to GLP-1RA and SGLT2 inhibitor treatments. Plasma protein glycosylation changes were more limited, with distinct alterations observed for each therapy. Metformin and GLP-1RA similarly reduced certain fucosylated and sialylated glycans, while SGLT2 inhibitors decreased a high-mannose glycan, previously positively associated with diabetes progression. Insulin therapy had a minimal effect on protein glycosylation, with only one plasma glycan significantly altered. Conclusions: Our findings emphasise the importance of protein glycosylation as a dynamic and responsive marker in T2D treatment. The distinct glycan alterations observed in response to metformin, SGLT2 inhibitors, and GLP-1 receptor agonists provide novel insights into the molecular effects of these therapies, potentially contributing to the development of glycan-based biomarkers for personalized diabetes management. What is already known on this topic?: ✓ Protein glycosylation is known to regulate multiple processes related to glucose homeostasis. ✓ Previous studies have shown that the IgG and plasma protein N-glycome (the entire set of N-glycans covalently attached to the IgG and plasma proteins, respectively) can help identify individuals at increased cardiometabolic risk. ✓ Despite most T2D patients receiving antidiabetic treatment, research on its effects on protein glycosylation remains scarce. What this study adds?: ✓ It is the first study to explore the effects of SGLT2 inhibitor and GLP-1RA therapy on protein glycosylation. ✓ The cardioprotective effects of these drug classes were also reflected in IgG glycosylation, demonstrated by increased monogalactosylation. ✓ Metformin, SGLT2 inhibitors, and GLP-1RA induce significant increase in IgG core fucosylation, a feature associated with reduced inflammatory IgG potential, possibly suggesting a shared pathway in suppressing inflammatory response. How this study might affect research, practice or policy?: ✓ The observed alterations in protein glycosylation across different therapeutic groups highlight its dynamic nature in response to metabolic interventions. ✓ Given the role of glycans in modulating immune function and inflammation, these findings suggest that glycan alterations could serve as potential biomarkers for assessing therapeutic response and disease progression in T2D. ✓ Future studies involving protein glycosylation should account for the potential confounding effects of antidiabetic medications to ensure accurate interpretations.

16 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DMDomagoj Mišković
Domagoj Mišković
NMNikol Mraz
Nikol Mraz
BTBarbara Radovani Trbojević
Barbara Radovani Trbojević
IJIvana Jurin
Ivana Jurin
AHAna Đanić Hadžibegović
Ana Đanić Hadžibegović
IHIrzal Hadžibegović
Irzal Hadžibegović
Background/Objective: Immunoglobulin G (IgG) N-glycosylation is an important regulator of immune function and systemic inflammation and has been associated with cardiometabolic diseases. However, little is known about how IgG glycosylation changes during the course of acute coronary syndrome (ACS) and whether these alterations relate to lipid-lowering response after the initiation of statin therapy. The primary aim of this study was to investigate IgG N-glycosylation following ACS and evaluate its association with response to atorvastatin therapy defined as baseline LDL cholesterol reduction of ≥50%. Methods: In this prospective cohort study, 79 statin-naïve patients hospitalized for the first episode of ACS and treated with atorvastatin 80 mg daily after percutaneous coronary intervention were followed longitudinally. Plasma samples were collected at admission (acute phase), discharge (subacute phase), and follow-up (chronic phase). A control group of 21 individuals received atorvastatin for primary prevention. IgG was isolated from plasma, and N-glycans were released, fluorescently labeled with 2-aminobenzamide, and analyzed using hydrophilic interaction-based ultra-high-performance liquid chromatography with fluorescence detection. Derived glycan traits were calculated, including agalactosylated (G0), monogalactosylated (G1), digalactosylated (G2), core fucosylated (F), bisected (B), and sialylated (S) glycans. Results: No significant differences in derived IgG glycan traits were observed between ACS patients and controls at baseline or follow-up. Within the ACS group, a longitudinal analysis revealed significant increases in G0 and F and a decrease in G2 between the acute and chronic phases. A total of 65% of patients achieved ≥50% reduction in LDL cholesterol (LDL-C), whereas only 22% reached the guideline-recommended LDL-C target of 3.9 mmol/L, those who failed to achieve ≥50% LDL-C reduction had significantly lower G0 and higher S across all time points. Conclusions: Specific glycan traits are associated with the degree of LDL-C reduction achieved during statin therapy, particularly in patients with high baseline LDL-C. These findings suggest that IgG glycosylation patterns may reflect biological phenotypes associated with differential lipid-lowering responsiveness after ACS.

Verified
Journal Article
Open access
PDF file
LKLovro Kavur
Lovro Kavur
TKThomas Klarić
Thomas Klarić
NMNikol Mraz
Nikol Mraz
NŠNina Šimunić-Briški
Nina Šimunić-Briški
DLDora Lalić
Dora Lalić
OGOzren Gamulin
Ozren Gamulin
Malignant pleural mesothelioma (MPM) is an aggressive pleural tumor associated with asbestos exposure. Poor clinical outcome of MPM is often driven by late-stage diagnosis due to non-specific clinical presentation, similarity to pleural lesions (e.g., inflammatory changes, metastatic adenocarcinoma), and limitations of current diagnostic methods. We employed Fourier transform infrared (FTIR) spectroscopy combined with convolutional neural networks (CNNs) to analyze formalin-fixed paraffin-embedded (FFPE) pleural tissue samples from patients with MPM, metastatic adenocarcinoma, pleural inflammation, and normal (healthy) pleura. Glycan analysis of FFPE normal pleura and MPM was performed using ultra-high-performance liquid chromatography (UPLC) and mass spectrometry (MS). Our FTIR-spectral analysis uncovered a strong spectral fingerprint of MPM that was especially apparent in the region typical for C-O and C-C stretches as well as local symmetry region typical for deformation vibrations of CH2 and C-OH groups, all appearing in carbohydrates. Our orthogonal validation of these findings through a targeted glycomics approach using UPLC confirmed that the MPM N-glycome exhibits a distinct fingerprint that distinguishes it from normal pleural tissue. Through utilization of MS for identifying the exact structures of differentially expressed N-glycan peaks, we also identified two high-mannose N-glycan structures that show a specific biomarker potential for MPM and need to be examined in future studies.